XXXX in Romania: a single-centre experience.

@entity1 @entity706 @entity784 @entity1072 @entity1892 @entity6444 @entity1073 @entity1893
UNASSIGNED: Epidemiologic studies of @entity1893 ( @entity1893 ) in Eastern Europe are scarce in the literature. We report the experience of the "Ion Chiricuta" Institute of Oncology in Cluj-Napoca (IOCN), Romania, in the diagnosis and outcome of @entity1 with @entity1893 . We studied 184 consecutive @entity1893 @entity1 diagnosed in the Pathology Department of IOCN during the years 2004-2006. We also obtained epidemiological data from the Northwestern (NW) Cancer Registry. In the IOCN series, the most common @entity706 subtype was diffuse large @entity1892 (43.5%), followed by the @entity6444 /small @entity1072 (21.2%). @entity784 represented a small proportion (8.2%). The median age of the @entity1 was 57   years, with a male-to-female ratio of 0.94. @entity1 with indolent @entity1892 had the best overall survival, whereas those with @entity1073 had the worst survival. The NW Cancer Registry data showed that the occurrence of @entity1893 in the NW region of Romania was higher in @entity1 [world age-standardized incidence rate/100   000 (ASR)-5.9; 95% CI 5.1-6.6] than in @entity1 (ASR-4.1; 95% CI 3.5-4.7) with age-standardized male-to-female ratio of 1.44 (p   =   0.038). @entity6444 /small @entity1072 was the most common @entity1893 in the NW region of Romania, accounting for 43% of all cases, followed by diffuse large @entity1892 (36%). The 5-year, age-standardized cumulative relative survival for @entity1893 in the County of Cluj in NW Romania, for the period of 2006-2010, was 51.4%, with 58.4% survival for @entity1 and 43.2% for @entity1 . Additional studies of @entity1893 in Eastern Europe are needed. Copyright    2015 John Wiley _ Sons, Ltd.
